BiotechTube

Valbenazine

Phase 3Completed
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tardive Dyskinesia

Conditions

Tardive Dyskinesia

Trial Timeline

Jun 13, 2016 → Jun 30, 2017

NCT ID
NCT02736955

About Valbenazine

Valbenazine is a phase 3 stage product being developed by Neurocrine Biosciences for Tardive Dyskinesia. The current trial status is completed. This product is registered under clinical trial identifier NCT02736955. Target conditions include Tardive Dyskinesia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (8)

NCT IDPhaseStatus
NCT07105111ApprovedRecruiting
NCT05053321Phase 1Withdrawn
NCT06312189Phase 3Recruiting
NCT05859698ApprovedCompleted
NCT04400331Phase 3Active
NCT03444038Phase 2Completed
NCT02879578Phase 2Completed
NCT02736955Phase 3Completed

Competing Products

13 competing products in Tardive Dyskinesia

See all competitors
ProductCompanyStageHype Score
SarizotanMerckPre-clinical
23
levetiracetam + placeboUCBPhase 3
74
ValbenazineNeurocrine BiosciencesPhase 1
30
Valbenazine Oral CapsuleNeurocrine BiosciencesApproved
82
NBI-98854 + NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
NBI-98854 + NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
NBI-98854Neurocrine BiosciencesPhase 3
74
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesApproved
82
NBI-98854Neurocrine BiosciencesPhase 2
49
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 3
74
NBI-98854 + NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesApproved
82
NBI-1065890 + PlaceboNeurocrine BiosciencesPhase 2
49

Other Products from Neurocrine Biosciences

Valbenazine Oral CapsuleApproved
82
ValbenazineApproved
82
ValbenazineApproved
82
Valbenazine + Placebo oral capsuleApproved
82
Valbenazine + Placebo oral capsuleApproved
82